Abstract 313P
Background
Outcome of recurrent/metastatic gynaecological cancer has drastically improved with introduction of PARP inhibitors and immunotherapy; but use of these drugs in routine practice is very difficult due to access barrier and high cost in developing countries. We aimed to present response, treatment outcome and safety of oral metronomic chemotherapy (OMCT) in a financially challenged, resource limited population.
Methods
This is a retrospective study on patients with advanced gynaecological cancer treated at Chittaranjan National Cancer Institute, Kolkata-West Bengal from 2021-2023; with either split course tablet Cyclophosphamide (50 mg once daily orally for 21 days) and tablet Capecitabine (500 mg twice daily orally continuous) or fixed dose combination (1800 mg +80 mg orally for 14 days in every 21 days) till disease progression or unacceptable toxicities. All data captured from medical records of hospital up till June 2023. Toxicity data was reported as per CTCAE V5 and progression free survival (PFS) was estimated using Kaplan Meier methods.
Results
Among 32 screened patients; 9 excluded due to noncompliance. 24 patients were analysed with median age at diagnosis of 56 years (IQ range 44-75). 16 (67%) patients were stage IV diseases with ECOG performance status 3. Ovarian and cervical cancer were 80% and 20% respectively; among them 16 (67%) patients were platinum refractory. 42% patients received three prior lines of chemotherapy before OMCT. Spit course versus fixed dose were given 67% versus 33% of population with best response were CR in 12%, PR 67%, SD 21% as per RECIST v1.1. Most common toxicities were Grade I anaemia (54%), grade I CINV (46%), grade I fatigue (42%) and grade I neutropenia (21%). 25% of patients were offered next line systemic therapy after progression. Median PFS was 9 months (95% CI 5.2-12.7) of entire cohort. Cox regression analysis identified median PFS of 12 months (95% CI 6.2-17.7) among platinum refractory group.
Conclusions
This OMCT was well-tolerated, affordable regimen with durable clinical response and survival outcome in recurrent refractory advanced gynaecological cancer and can be offered among patients in resource limited centres.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract